本文選題：急性白血病 + 微小殘留病��； 參考：《中國實(shí)驗(yàn)血液學(xué)雜志》2017年03期

【摘要】：目的:研究非清髓造血干細(xì)胞移植(NST)前后采用流式細(xì)胞術(shù)(FCM)動(dòng)態(tài)監(jiān)測(cè)微小殘留病(MRD),以預(yù)測(cè)移植后急性白血病(AL)復(fù)發(fā)的意義,為臨床早期干預(yù)提供指導(dǎo)。方法:回顧性研究2011年1月至2015年12月在軍事醫(yī)學(xué)科學(xué)院附屬醫(yī)院血液科行NST的成人AL患者51例,對(duì)所有患者移植前骨髓形態(tài)學(xué)完全緩解(CR)期內(nèi),移植前35 d內(nèi)、移植后1、2、3月內(nèi),以后每3月至移植后2年、2年后每6個(gè)月內(nèi)采集骨髓監(jiān)測(cè)MRD。低水平MRD組(A組)共33例(移植后每次檢測(cè)MRD0.2%),高水平MRD組(B組)共18例(移植后動(dòng)態(tài)監(jiān)測(cè)MRD,至少1次≥0.2%)。結(jié)果:移植后2組2年累計(jì)復(fù)發(fā)率分別為6.1%和50%(P=0.001)。多因素分析表明:移植后M RD≥0.2%是AL移植后復(fù)發(fā)的獨(dú)立的高危因素,高水平MRD組復(fù)發(fā)風(fēng)險(xiǎn)是低水平MRD組的5.84倍(P=0.036)。移植后復(fù)發(fā)組與未復(fù)發(fā)組的死亡率分別為81.8%和46.3%(P=0.036)。結(jié)論:非清髓異基因造血干細(xì)胞移植治療急性白血病中,采用FCM動(dòng)態(tài)監(jiān)測(cè)MRD是預(yù)測(cè)移植后早期復(fù)發(fā)的重要方法,移植后MRD≥0.2%可作為白血病早期復(fù)發(fā)的預(yù)警,以及指導(dǎo)臨床早期給予干預(yù)措施的重要依據(jù)。
[Abstract]:Objective: to study the dynamic monitoring of MRDV by flow cytometry (FCM) before and after non-myeloablative hematopoietic stem cell transplantation (NST) in order to predict the recurrence of acute leukemia (ALL) after transplantation and to provide guidance for early clinical intervention. Methods: a retrospective study of 51 adult AL patients who were treated with NST from January 2011 to December 2015 in Hematology Department of affiliated Hospital of the Academy of military Medical Sciences was conducted. The bone marrow morphology of all the patients was completely relieved before transplantation and 35 days before transplantation. Bone marrow monitoring MRDs were collected within 1 ~ 2 months, 3 months, 3 months, 2 years and 2 years after transplantation. There were 33 cases in low level MRD group (MRD 0. 2% after transplantation and 18 cases in high level MRD group B) (dynamic monitoring of MRD after transplantation, 鈮，

本文編號(hào)：1865689